AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06104436 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Usual technique for calming agitated older adults with dementia
Study NCT05860972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.
Description: After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
Study NCT05860972 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.
Description: After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
Study NCT06013046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-controlled physical activity training (IPAT)
Description: The IPAT group will receive 40 (90 minute) one-on-one, intensity-controlled, exercise sessions by trained staff over 14 weeks. The initial 2-week period will include dedicated education on topics including physical activity guidelines and the benefits of achieving them, the feeling of moderate-to-vigorous physical activity intensity levels, and the appropriate exercises for achieving desired intensity levels. Tailored sessions will be created for each participant based on their physical fitness, goals, preferred exercise equipment and results from their baseline assessment. Each session can include vitals, pain assessment, warm-up, aerobic training, strength exercises and a cool-down. The participants will be monitored to ensure they are achieving at least 150 minutes of moderate-to-vigorous intensity physical activity weekly. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. The overall goal is to improve cardiorespiratory fitness.
Study NCT06013046 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education and Access (EA)
Description: The EA group will receive an initial 60 minute educational session, during which they will receive information on the adapted exercise equipment in the Orthwein Center, education on the physical activity guidelines and the health benefits of achieving them, and access to the Orthwein Center accessible gym. They will then complete a 14-week independent workout program with the goal of meeting physical activities guidelines. They will have access to Orthwein Center staff to help with minimal setup and guidance, but sessions will be self-directed. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. Participants will be asked to complete a log for each session to report pain, details of the activities they completed during their workout, the RPE for each activity, and how long each activity lasted.
Study NCT04729023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy combined with cataract surgery.
Description: In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.
Study NCT04729023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy with subsequent cataract surgery.
Description: In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.
Study NCT05475730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone and soft tissue augmentation
Description: A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel.A pouch is create between the bone and the membrane and the mixed bone chips and hyaluronic acid are inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures.
Study NCT04806555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Compression ultrasound examination
Description: After successful revascularisation for acute ischemia and clinical suspicion of acute compartment syndrome, compression ultrasound (CU) will be performed in OR followed by standard intra-compartmental measurement. Two physicians will perform two subsequent measurements of the affected limb after revascularisation. The unaffected limb will be examined once to obtain baseline elasticity ratio values. All CU examinations will be documented in PACS (picture archiving and communication system) and evaluated after ICP measurement, and if necessary, fasciotomy is performed.
Study NCT06138496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab Combined With Lenvatinib
Description: 3.7.1 Lenvatinib Treatment Lenvatinib (8mg \[body weight \< 60 kg\] or 12 mg \[body weight ≥ 60 kg\]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles.
Study NCT04607317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day)
Study NCT04607317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coach
Description: The coach will work directly with each participant during their once-weekly virtual 1:1 meeting to progress intensity and duration. Participants will meet with the coach to review a brief social cognitive theory-based module, which will provide education on core behavior change concepts and the benefits of physical activity for those with epilepsy. The coach will review the previous week's exercise during meetings, and will then work with the participant to revise and reset goals for the coming week.
Study NCT04607317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Information
Description: Participants will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
Study NCT00992472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine suppositories, 25mg
Study NCT00992472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compazine® suppositories, 25mg
Study NCT04549129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding education video
Description: An introductory video (15 minutes) gives an overview of these ABCs (video titled Term baby which are further taught through brief text summaries (150-200 words) and short instructional videos (2-6 minutes).
Study NCT04549129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding website
Description: The website firstdroplets.com is designed for prenatal education, focusing on the ABCs of breastfeeding that come before D (delivery) - attachment (latch), breastmilk production, and calories (transfer of milk to baby).
Study NCT04549129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual breastfeed education
Description: The usual breastfeed education includes brief counseling by study staff and provision of handouts on latch/positioning and common first week breastfeeding advice
Study NCT04981990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single lung ventilation by double lumen endotracheal tube
Description: Single lung ventilation using double lumen endotracheal tube and isolation of the operated lung during surgery to create ideal surgical field
Study NCT04981990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two lung ventilation by conventional single lumen endotracheal tube
Description: Intermittent two lung ventilation so that no significant hypoxia occurs with creating optimum surgical field
Study NCT06435897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fetal MSCs combined with 4SCAR T cells
Description: Infusion of 4SCAR T cells at 10\^6 cells/kg body weight and MSCs at 3x10\^6 cells via IV
Study NCT04526769 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Collection
Description: A microcapillary tube will be placed at the corner of the eyelid so tears can be absorbed to the tube without causing any trauma. The tube will be placed in a transfer tube. Standard virus sampling swabs will be used to collect samples from the same patient's nasopharynx. RT-PCR will be run to determine virus yield in each sample.~For the second part of the study, IHC staining will be done on the existing ocular tissue pathology slides to detect the expression of ACE2 and other cell surface and intracellular receptors. The investigators will use existing UMN ocular pathology lab and Lion's Eye Bank tissue samples. These are banked tissue samples that were collected and examined previously and then the remaining tissue samples were stored.
Study NCT05568303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT techniques
Description: through CBT sessions , the participants apply problem solving process in managing their stressors . examining the role of cognitions, emotions, and behaviors to form cause and effect relationship of participants psychological distress
Study NCT05241548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMAC on PCL Scaffold
Description: Horizontal ridge augmentation in aesthetic zone by using bone marrow aspirate concentrate on PCL scaffold
Study NCT05219552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized lactation support
Description: Our intervention design aims to address food insecurity and mental health by providing an unconditional cash transfer and lactation support across the perinatal period, when women are out of the workforce caring for their infant child. The study will include pregnant women living with HIV in Kisumu Kenya. The lactation support component will focus on milk insufficiency primarily as that has been a main concern of women we've worked with in this population, in addition to general breastfeeding support which will all be delivered in one-on-one sessions with a professional lactation consultant. The cash transfer will be delivered to women from their third trimester to 6 months postpartum. The amount of the cash transfer is based on preliminary data and consultation with key stakeholders to determine a reasonable and sufficient amount to basic living expenses during this period.
Study NCT05874193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin 2.5mg/kg in 42-day cycles. Every 6 weeks until PD, unacceptable toxicity or withdrawal of consent, whichever comes first
Study NCT05755243 — intervention group
Intervention type: DEVICE
Intervention: glucose sensor
Description: skin biopsy (punch)
Study NCT05741749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Seal Abutment
Description: Customized Healing Abutment
Study NCT05741749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socket Seal Abutment
Description: Customized Healing Abutment
Study NCT06517355 — intervention group
Intervention type: OTHER
Intervention: In this research, the procedure under study is represented:
Description: * On the one hand, by carrying out sexology consultations which consist of individual interviews with a qualified sexologist nurse.~* Secondly, questionnaires to assess quality of life and sexual function, to be completed by patients during standard follow-up consultations; and a questionnaire on satisfaction with sexological follow-up, to be completed by patients and their partners (if applicable) during the last standard follow-up consultation.
Study NCT06353555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euthyrox
Description: Upon discovering low T3 or low T4 levels, administer oral levothyroxine sodium tablets daily. If accompanied by a decrease in TSH, the regimen is 100μg qd (for individuals weighing \<75kg) or 150μg qd (for individuals weighing >75kg). If not accompanied by a decrease in TSH, the regimen is 50μg qd. However, if thyroid function does not significantly improve within 3 days of medication, the regimen is adjusted to 100μg qd. Treatment should continue until transfer out of the NICU or discharge, with a minimum duration of 7 days.
Study NCT06353555 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Euthyrox
Description: Patient will not receive the oral levothyroxine sodium tablets.
Study NCT04502680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
Study NCT06458478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyper-oxygenated gel
Description: Novox drop is a medical device (CE certified, class II b, non-invasive) based on oxygen-enriched olive oil (Excipients: Mint essential oil (2%), Stevia extract (1%)). Mechanism of action: facilitate the healing process by creating, thanks to the release of reactive oxygen species (ROS), a microenvironment favorable to the activation of the microcirculation and at the same time unfavorable to the proliferation of pathogens. Furthermore, it has a film-forming, protective, barrier and soothing action thanks to its oily nature.
Study NCT06458478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glycerin based gel
Description: The placebo consists of a viscous, colorless and transparent gel, based on glycerin (Conformity:FUI).
Study NCT04900727 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05699694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: StemRegen product
Description: Products will be consumed orally in capsules with a glass of water. Six capsules per day will be consumed daily for 6 month. Two main administration schedules are possible:~Two in the morning, 2 at noon, and 2 in the evening at each meal depending on individual habits of the volunteers to reduce non-compliance.
Study NCT06464978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stapler Reinforcement Patch
Description: Participants in this group will receive gastrojejunostomy with the use of stapler reinforcement patches.
Study NCT06464978 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Stapler
Description: Participants in this group will receive gastrojejunostomy with the use of Standard Stapler
Study NCT05428397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: X-Ray/CT Diagnostic Imaging
Study NCT04794569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinzaparin
Description: low molecular weight heparin
Study NCT04794569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: direct oral anticoagulant
Study NCT05097872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet excluding either trigger and sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
Study NCT05097872 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diet
Description: Diet excluding either trigger and sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
Study NCT00012714 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Case management services
Study NCT05291871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: One-fifth dose bivalent HPV Vaccine or One-fifth dose nonavalent HPV Vaccine
Study NCT05239780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain stimulation
Description: Brain stimulation will be performed after collection of clinical seizure data. Bipolar stimulation to one or several adjacent electrodes will be applied. Stimulation design will be either determined prior to testing or designed according to results from neurobehavioral assessments. Stimulation will consist of biphasic, constant-current trains of stimulation pulses at 100 Hz, with 100 ms pulse width or a sinusoidal wave of a predefined mean band frequency (i.e. 6Hz for θ, 11Hz for α, 20Hz for β, etc.). Stimulation intensity will be ≤6 mA, consistent with parameters used for clinical mapping, for the duration of the behavioral task or for short (2-3 s) periods of time at given epochs during the task (i.e. outcome evaluation). Clinical personnel will be available during stimulation to help monitor stimulation-induced after-discharges; if any are detected, stimulation intensity will be dialed down or terminated.
Study NCT06411314 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories
Description: 1 suppository once daily at bedtime for 6 days
Study NCT06411314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose 300 mg vaginal suppositories
Description: 1 suppository once daily at bedtime for 6 days
Study NCT06411314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimafucin® (natamycin) 100 mg vaginal suppositories
Description: 1 suppository once daily at bedtime for 6 days
Study NCT05840757 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HemoSphere ClearSight Module
Description: The Clear Sight system consists of a finger cuff connected to a monitor It will be applied to the patients finger before and removed after the TAVI procedure.
Study NCT06265662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Digital Health Program for Non-Communicable Disease Prevention in a Workplace Setting in Thailand
Description: The program consists of two main components: (1) Participants are invited to join health courses and/or health activities in the form of seminars or group activities, and (2) Participants will have access to an application that is part of the program, where they can consult with health experts to plan lifestyle modifications and reduce behavioral risk factors over the 6-month duration of the research project, totaling four sessions, each lasting one hour.
Study NCT05834829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound neuromodulation
Description: ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.
Study NCT05834829 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-intensity focused ultrasound
Description: sham application of ultrasound using blocking of the ultrasound waves of the transducer.
Study NCT05404932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliquoted allogeneic donor plasma in patient's conjunctiva
Description: 1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
Study NCT05835817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography
Description: 40 minutes of Magnetoencephalography with Optical Pump Magnetometer
Study NCT06233266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor-Test product
Description: Ticagrelor Tablets 90 mg Manufactured by: Mankind Pharma Limited, India
Study NCT06233266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor-Reference product
Description: Ticagrelor Tablets 90 mg Manufactured by: AstraZeneca AB, Sweden
Study NCT03567213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical implantation of CortiCom system
Description: Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
Study NCT04826796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp peer support
Description: Trained peer supporters will provide breastfeeding and emotional support for participants in the WhatsApp group.
Study NCT04971096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 live
Description: PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23
Study NCT04971096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 heat-treated
Description: The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.
Study NCT04971096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule contains microcrystalline cellulose.
Study NCT05861648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid Oral Tablet
Description: Dietary Supplement: Folic acid 2.5mg/day
Study NCT05861648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary Supplement: Placebo